MFDS Launches Special Task Force to Inspect Obesity Treatment Sales

The Ministry of Food and Drug Safety will step up inspections of the illegal online sale, brokerage, and advertising of glucagon-like peptide-1 (GLP-1) obesity treatments. It also plans to impose strict penalties, including referring cases for investigation and filing complaints, against people who resell in Korea products they personally brought in from overseas.


A pharmacist explains the obesity treatment Wegovy at Saejongno Pharmacy in Jongno-gu, Seoul. Yonhap News Agency

A pharmacist explains the obesity treatment Wegovy at Saejongno Pharmacy in Jongno-gu, Seoul. Yonhap News Agency

View original image

On November 19, the Ministry of Food and Drug Safety said it had established and would operate a special task force to inspect the illegal sale of obesity treatments, responsible for monitoring, on-site inspections, and investigations. The special task force consists of an online monitoring team, an on-site inspection team, and an investigation team. It will also operate a reporting center where people can report known cases of illegal obesity treatment sales.


The special task force will focus on posts that attract consumers by promoting weight loss or obesity treatment. These include posts brokering or advertising illegal online sales; introducing sales websites through online communities and blogs; private secondhand transactions; and posts that encourage one-on-one chats on social networking services (SNS) to sell obesity treatments. The task force plans to immediately request that the Broadcasting Media Communications Review Committee and other relevant bodies block posts it uncovers.


In particular, if someone does not use a product they personally purchased overseas for self-treatment and brought into Korea, but instead resells it domestically or gives it to an acquaintance, this constitutes a violation of the Pharmaceutical Affairs Act. Violators may face up to five years in prison or a fine of up to 50 million won.


GLP-1 obesity treatments are medicines that increase insulin secretion and suppress glucagon secretion in response to glucose. They have recently drawn public attention because they can delay hunger and reduce body weight. However, they are prescription medicines and must be prescribed at a hospital or clinic, obtained from a pharmacy, and administered at the specified dose and according to the specified instructions, following a pharmacist's guidance on their use. Information on the efficacy and effects, dosage and administration, and precautions for medicines approved in Korea can be found by searching for the product or ingredient name on the Drug Safety Korea website.



An official from the Ministry of Food and Drug Safety said, "People should take particular care not to distribute or purchase obesity treatments through private sales or other means." The official added, "Medicines brought into the country in a person's baggage should be prescribed and purchased on a limited basis, only when essential for treating an illness, and should preferably be used only within the scope approved in Korea and in accordance with a doctor's prescription."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing